title: [Conservative treatment of Peyronie's disease in the light of new pathogenetic data].
abstract: The study of pathogenetic mechanisms of Peyronie's disease (PD) in respect of raising efficacy of complex conservative therapy was made in 41 patients with PD. The control group consisted of 266 persons. Immunological and virusological investigations were made using enzyme immunoassay. HLA typing of class I antigens was made, antinuclear antibodies and antibodies to DNA were investigated. Effects of intron A and verapamil on proliferation of penile tunica albuginea were studied in vitro. Conservative therapy was given to 32 patients with acute PD. Patients with PD were found to carry chronic infection with type II herpes significantly more frequently. There was a significant association of PD with HLA-antigen B8 with high percentage of diagnostic titers of antinuclear antibodies. In vitro effect of intron A and verapamil was found to be dose- and time-dependent. Verapamil has a narrow range of dose-dependence and cytotoxicity in high concentrations. Combined treatment raised the proportion of good results while that of satisfactory outcomes decreased. Viral infection may be involved in pathogenesis of PD. This infection may alter mechanisms of immune regulation and start of autoimmune process in predisposed patients. Combination of magnetolaser therapy with intron A injections is an effective method of acute PD treatment. The addition of specific antiviral therapy raises treatment efficacy by action on one of pathogenetic mechanisms of the disease.
authors.forename: E B
authors.initials: EB
authors.lastname: Mazo
authors.forename: M L
authors.initials: ML
authors.lastname: Mufaged
authors.forename: L P
authors.initials: LP
authors.lastname: Ivanchenko
authors.forename: E A
authors.initials: EA
authors.lastname: Kalashnikova
authors.forename: S M
authors.initials: SM
authors.lastname: Terekhov
mesh_terms: D000328:Adult; D000368:Aged; D000974:Antibodies, Antinuclear / Q000097:blood; D000998:Antiviral Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D052203:Ferrosoferric Oxide / Q000627:therapeutic use; D006680:HLA Antigens / Q000032:analysis; D006558:Herpes Genitalis / Q000150:complications / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000493:pharmacokinetics / Q000627:therapeutic use*; D053685:Laser Therapy; D008297:Male; D008875:Middle Aged; D010411:Penile Induration / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D011994:Recombinant Proteins; D014665:Vasodilator Agents / Q000627:therapeutic use*; D014700:Verapamil / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000974:Antibodies, Antinuclear; D000998:Antiviral Agents; D006680:HLA Antigens; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D014665:Vasodilator Agents; D014700:Verapamil; D052203:Ferrosoferric Oxide